• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TIM-3在急性髓系白血病诊断性骨髓中自然杀伤细胞上的表达的功能作用及预后意义

The Functional Role and Prognostic Significance of TIM-3 Expression on NK Cells in the Diagnostic Bone Marrows in Acute Myeloid Leukemia.

作者信息

Sun Kai, Shi Zong-Yan, Xie Dai-Hong, Wang Ya-Zhe, Jiang Hao, Jiang Qian, Huang Xiao-Jun, Qin Ya-Zhen

机构信息

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.

出版信息

Biomedicines. 2024 Nov 27;12(12):2717. doi: 10.3390/biomedicines12122717.

DOI:10.3390/biomedicines12122717
PMID:39767624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11727352/
Abstract

Compared to other immune checkpoint molecules, T cell immunoglobulin domain and mucin domain-3 (TIM-3) is highly expressed on natural killer (NK) cells, but its functional role and prognostic significance in acute myeloid leukemia (AML) remains unclear. This study aims to evaluate the role of TIM-3 expression on the cytotoxic and killing capacity of NK cells and its prognostic significance in AML. AML public single-cell RNA sequencing (scRNAseq) data were used to analyze the correlation of transcript levels between (encoding TIM-3) and cytotoxic molecules in NK cells. NK cells from the bone marrows of seven newly diagnosed AML patients and five healthy donors (HDs) were stimulated in vitro and cell-killing activity was evaluated. A total of one hundred and five newly diagnosed adult AML patients and seven HDs were tested the expression of TIM-3 and cytotoxic molecules on the bone marrow NK cells by multi-parameter flow cytometry (MFC). Both scRNAseq and MFC analysis demonstrated that TIM-3 expression on NK cells was positively related to the levels of perforin (PFP) and granzyme B (GZMB) (all < 0.05) in AML. It was PFP and GZMB but not the TIM-3 level that was related to NK-cell-killing activity against K562 cells ( = 0.027, 0.042 and 0.55). A high frequency of TIM-3 NK cells predicted poorer relapse-free survival (RFS) and event-free survival (EFS) ( = 0.013 and 0.0074), but was not an independent prognostic factor, whereas low GZMB levels in TIM-3 NK cells independently predicted poorer RFS ( = 0.0032). TIM-3 expression on NK cells is positively related to PFP and GZMB levels but has no relation to cell-killing activity in AML, and low GZMB levels in TIM-3 NK cells in the diagnostic bone marrows predicts poor outcomes. This study lays a theoretical foundation for the clinical application of immune checkpoint inhibitor treatment.

摘要

与其他免疫检查点分子相比,T细胞免疫球蛋白结构域和粘蛋白结构域3(TIM-3)在自然杀伤(NK)细胞上高表达,但其在急性髓系白血病(AML)中的功能作用和预后意义仍不清楚。本研究旨在评估TIM-3表达对NK细胞细胞毒性和杀伤能力的作用及其在AML中的预后意义。利用AML公共单细胞RNA测序(scRNAseq)数据来分析NK细胞中(编码TIM-3)转录水平与细胞毒性分子之间的相关性。对7例新诊断的AML患者和5例健康供者(HD)骨髓中的NK细胞进行体外刺激并评估细胞杀伤活性。通过多参数流式细胞术(MFC)检测了105例新诊断的成年AML患者和7例HD骨髓NK细胞上TIM-3和细胞毒性分子的表达。scRNAseq和MFC分析均表明,AML中NK细胞上的TIM-3表达与穿孔素(PFP)和颗粒酶B(GZMB)水平呈正相关(均P<0.05)。与NK细胞对K562细胞的杀伤活性相关的是PFP和GZMB水平,而不是TIM-3水平(P=0.027、0.042和0.55)。高频率的TIM-3 NK细胞预示着无复发生存期(RFS)和无事件生存期(EFS)较差(P=0.013和0.0074),但不是独立的预后因素,而TIM-3 NK细胞中低水平的GZMB独立预示着较差的RFS(P=0.0032)。AML中NK细胞上的TIM-3表达与PFP和GZMB水平呈正相关,但与细胞杀伤活性无关,诊断骨髓中TIM-3 NK细胞的低GZMB水平预示着不良预后。本研究为免疫检查点抑制剂治疗的临床应用奠定了理论基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de9c/11727352/6675d4004f8c/biomedicines-12-02717-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de9c/11727352/782f7ce04c64/biomedicines-12-02717-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de9c/11727352/3a8b7345bc9d/biomedicines-12-02717-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de9c/11727352/5227962fc612/biomedicines-12-02717-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de9c/11727352/50c26d215679/biomedicines-12-02717-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de9c/11727352/6675d4004f8c/biomedicines-12-02717-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de9c/11727352/782f7ce04c64/biomedicines-12-02717-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de9c/11727352/3a8b7345bc9d/biomedicines-12-02717-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de9c/11727352/5227962fc612/biomedicines-12-02717-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de9c/11727352/50c26d215679/biomedicines-12-02717-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de9c/11727352/6675d4004f8c/biomedicines-12-02717-g005.jpg

相似文献

1
The Functional Role and Prognostic Significance of TIM-3 Expression on NK Cells in the Diagnostic Bone Marrows in Acute Myeloid Leukemia.TIM-3在急性髓系白血病诊断性骨髓中自然杀伤细胞上的表达的功能作用及预后意义
Biomedicines. 2024 Nov 27;12(12):2717. doi: 10.3390/biomedicines12122717.
2
The Functional and Prognostic Impact of TIGIT Expression on Bone Marrow NK Cells in Core Binding Factor-Acute Myeloid Leukemia Patients at Diagnosis.TIGIT表达对初诊核心结合因子急性髓系白血病患者骨髓自然杀伤细胞的功能及预后影响
Biomedicines. 2024 Sep 27;12(10):2207. doi: 10.3390/biomedicines12102207.
3
Features and prognostic significance of soluble TIM-3 and its ligands Gal-9 and CEACAM1 levels in the diagnostic bone marrow of adult acute myeloid leukemia patients.成人急性髓系白血病患者诊断性骨髓中可溶性TIM-3及其配体Gal-9和CEACAM1水平的特征及预后意义
J Leukoc Biol. 2024 Dec 31;117(1). doi: 10.1093/jleuko/qiae191.
4
Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.t(8;21)急性髓系白血病患者诊断时TIM-3表达模式的预后意义
Leuk Lymphoma. 2022 Jan;63(1):152-161. doi: 10.1080/10428194.2021.1966785. Epub 2021 Aug 18.
5
[Expression of Tim-3 on natural killer cells in patients with acute myeloid leukemia and its clinical significance].[急性髓系白血病患者自然杀伤细胞上Tim-3的表达及其临床意义]
Zhonghua Xue Ye Xue Za Zhi. 2019 Sep 14;40(9):755-758. doi: 10.3760/cma.j.issn.0253-2727.2019.09.009.
6
Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.Tim-3在急性髓系白血病的T细胞中高表达,并与临床病理预后分层相关。
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6880-8. eCollection 2014.
7
Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.新诊断急性髓系白血病白血病细胞及肿瘤微环境中 TIM-3 和 PD-1/PD-L1 表达的特征及临床相关性。
Leuk Lymphoma. 2022 Feb;63(2):450-456. doi: 10.1080/10428194.2021.1984454. Epub 2021 Sep 29.
8
The effect of TIGIT and PD1 expression on T cell function and prognosis in adult patients with acute myeloid leukemia at diagnosis.TIGIT和PD1表达对初诊成年急性髓系白血病患者T细胞功能及预后的影响。
Cancer Immunol Immunother. 2025 Apr 11;74(5):170. doi: 10.1007/s00262-025-04024-0.
9
Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.急性髓系白血病和骨髓增生异常综合征中的自然杀伤细胞(NK)亚群及NK样T细胞群体
Cytometry B Clin Cytom. 2016 Jul;90(4):349-57. doi: 10.1002/cyto.b.21349. Epub 2016 Feb 3.
10
TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes.急性髓系白血病原始细胞上TIM-3的表达水平与核心结合因子易位的存在相关,而非与临床结果相关。
Front Oncol. 2022 Apr 14;12:879471. doi: 10.3389/fonc.2022.879471. eCollection 2022.

引用本文的文献

1
The expression patterns and prognostic significance of PD-1 and TIM-3 on T cells and the differentiated subsets in acute myeloid leukemia.急性髓系白血病中T细胞及分化亚群上PD-1和TIM-3的表达模式与预后意义
Ann Hematol. 2025 May 27. doi: 10.1007/s00277-025-06418-7.

本文引用的文献

1
Global, regional, and national burden of acute myeloid leukemia, 1990-2021: a systematic analysis for the global burden of disease study 2021.1990 - 2021年全球、区域和国家急性髓系白血病负担:全球疾病负担研究2021的系统分析
Biomark Res. 2024 Sep 11;12(1):101. doi: 10.1186/s40364-024-00649-y.
2
Phase-Based and Lifetime Health System Costs of Care for Patients Diagnosed with Leukemia and Lymphoma: A Population-Based Descriptive Study.基于阶段和终生的白血病和淋巴瘤患者护理的健康系统成本:一项基于人群的描述性研究。
Curr Oncol. 2024 Jul 25;31(8):4192-4208. doi: 10.3390/curroncol31080313.
3
Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia.
KIT 基因突变转录本水平在 t(8;21)急性髓系白血病微小残留病监测中的作用
Hematol Oncol. 2024 Mar;42(2):e3264. doi: 10.1002/hon.3264.
4
Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.伴有 runt 相关转录因子 1 突变的急性髓系白血病患者的临床特征和预后:一项单中心回顾性分析。
Hematol Oncol. 2024 Mar;42(2):e3256. doi: 10.1002/hon.3256.
5
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation.LAG-3、TIM-3 和 TIGIT:免疫调节中的不同功能。
Immunity. 2024 Feb 13;57(2):206-222. doi: 10.1016/j.immuni.2024.01.010.
6
The rise of TIM-3: A promising immune target in diffuse midline gliomas.TIM-3的兴起:弥漫性中线胶质瘤中一个有前景的免疫靶点。
Clin Transl Med. 2024 Jan;14(1):e1536. doi: 10.1002/ctm2.1536.
7
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.沙妥利单抗联合低甲基化药物治疗未经治疗的高危骨髓增生异常综合征患者(STIMULUS-MDS1):一项随机、双盲、安慰剂对照、2 期临床试验。
Lancet Haematol. 2024 Jan;11(1):e38-e50. doi: 10.1016/S2352-3026(23)00333-2. Epub 2023 Dec 5.
8
Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.来自工程诱导多能干细胞的抗TIM3嵌合抗原受体自然杀伤细胞可有效靶向急性髓系白血病细胞。
Cancer Cell Int. 2023 Nov 27;23(1):297. doi: 10.1186/s12935-023-03153-9.
9
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.Sabatolimab(MBG453)是一种新型免疫疗法,针对 TIM-3 抗体,与地西他滨或阿扎胞苷联合治疗高危或极高危骨髓增生异常综合征的 Ib 期研究。
Am J Hematol. 2024 Feb;99(2):E32-E36. doi: 10.1002/ajh.27161. Epub 2023 Nov 22.
10
Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia.IFN-γ+ T 细胞中 PD-1/Tim-3 表达升高与急性髓系白血病患者预后不良相关。
Cancer Biol Ther. 2023 Dec 31;24(1):2278229. doi: 10.1080/15384047.2023.2278229. Epub 2023 Nov 14.